N-Acetyl Cysteine (NAC) 관련 Inflammatory Bowel Disease (IBD) — General
DPilot data only. Glutathione precursor may reduce oxidative stress in IBD. Requires larger clinical trials.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dn\u002Dacetyl\u002Dcysteine\u0026condition\u003Dinflammatory\u002Dbowel\u002Ddisease';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
D
결론
Pilot data only. Glutathione precursor may reduce oxidative stress in IBD. Requires larger clinical trials.
Key Study Findings
Review
Nanocatalytic Antioxidation: A General Chemical Approach for Alleviating Oxidative Stress in Diseases.
Dose: None
vs: None
Outcome: None
효과: None
None
대상 집단: Review of nanocatalytic antioxidation in diseases
Randomized Controlled Trial
16 weeks
Open-label
Exploring the role of oxidative stress and the effect of N-acetylcysteine in thiopurine-induced liver injury …
Dose: N-acetylcysteine with thiopurine
vs: Thiopurine alone (crossover)
Outcome: Liver injury markers and oxidative stress
효과: None
None
대상 집단: IBD patients with thiopurine-induced liver injury
Review
The emerging role of oxidative stress in inflammatory bowel disease.
Dose: None
vs: None
Outcome: Oxidative stress role in IBD pathophysiology
효과: None
None
대상 집단: IBD patients (Crohn's and UC)
In Vitro
4.3 weeks
Extraintestinal Manifestations in Induced Colitis: Controversial Effects of N-Acetylcysteine on Colon, Liver, and Kidney.
Dose: 150 mg/kg
vs: None
Outcome: inflammation markers
효과: None
None
대상 집단: Mice
Systematic Review
52 weeks
Vitamin D for the treatment of inflammatory bowel disease.
Dose: 400 IU/day
vs: placebo
Outcome: IBD disease activity
효과: None
None
대상 집단: Patients with IBD
Review
Role of ferroptosis in the pathogenesis and as a therapeutic target of inflammatory bowel disease …
Dose: None
vs: None
Outcome: Ferroptosis role in IBD pathogenesis
효과: None
None
대상 집단: IBD patients (mechanistic review)
Key Statistics
1
연구
30
참여자
↑
Positive
D
등급
Referenced Papers
Accounts of chemical …
2025
2 인용
Frontiers in endocrinology
2024
165 인용
Basic & clinical …
2024
International journal of …
2023
59 인용
Pharmaceuticals (Basel, Switzerland)
2023
18 인용
Oxidative medicine and …
2023
11 인용
Vitamin D for the treatment of inflammatory bowel disease.
Systematic Review
The Cochrane database …
2023
1 인용
Journal of nanobiotechnology
2022
206 인용
International immunopharmacology
2022
21 인용
Journal of biochemical …
2022
5 인용
Medwave
2022
4 인용
European journal of …
2021
40 인용
Journal of inflammation …
2021
34 인용
Journal of Crohn's …
2018
91 인용
Redox biology
2017
34 인용
Digestion
2016
522 인용
Chemical research in …
2015
13 인용
Scandinavian journal of …
2013
65 인용
The British journal …
2012
145 인용
World journal of …
2012
113 인용
Pharmaceutical biology
2010
16 인용
Digestive diseases and …
2009
49 인용
Molecular and cellular …
2007
95 인용
Journal of agricultural …
2007
44 인용
The Tohoku journal …
2005
114 인용
The Journal of …
2005
63 인용
Journal of leukocyte …
2002
Laboratory investigation; a …
2000
116 인용
Role of free radicals and poly(ADP-ribose) synthetase in intestinal tight junction permeability.
Other
Molecular medicine (Cambridge, …
2000
Alimentary pharmacology & …
1999
57 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 600-1,200 mg/day in divided doses
- hpyloriadjunct:
- 600 mg twice daily alongside standard triple therapy
- antioxidantsupport:
- 600-900 mg/day
상한량: Generally well-tolerated up to 1,800 mg/day; higher doses used in clinical settings
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| N-acetylcysteine with thiopurine | 16 weeks | Positive | -- |
| None | -- | Positive | -- |
| 150 mg/kg | 4.3 weeks | Positive | -- |
| 400 IU/day | 52 weeks | Mixed | -- |
| None | -- | Neutral | -- |
| Various antioxidant compounds | -- | Positive | -- |
| None | -- | Mixed | -- |
권장 복용 시간: With or without food; divide doses throughout the day
Safety & Side Effects
보고된 부작용
- ⚠ Nausea and vomiting (most common, especially at higher doses)
- ⚠ Diarrhea
- ⚠ Unpleasant sulfur taste/odor
- ⚠ Headache
알려진 상호작용
- ● Nitroglycerin (NAC may enhance vasodilatory effects; risk of hypotension)
- ● Activated charcoal (may reduce NAC absorption)
- ● Anticoagulants (NAC may have mild antiplatelet effects)
- ● ACE inhibitors (additive hypotensive effect with nitroglycerin combination)
일일 최대 섭취 허용량: Generally well-tolerated up to 1,800 mg/day; higher doses used in clinical settings
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does N-Acetyl Cysteine (NAC) help with Inflammatory Bowel Disease (IBD) — General?
Based on 1 studies with 30 participants, there is preliminary evidence that needs more research that N-Acetyl Cysteine (NAC) may support Inflammatory Bowel Disease (IBD) — General management. Our evidence grade is D (Very Early Research).
How much N-Acetyl Cysteine (NAC) should I take for Inflammatory Bowel Disease (IBD) — General?
Studies have used various dosages. A commonly studied range is 600-1,200 mg/day in divided doses. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of N-Acetyl Cysteine (NAC)?
Reported side effects may include Nausea and vomiting (most common, especially at higher doses), Diarrhea, Unpleasant sulfur taste/odor, Headache. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for N-Acetyl Cysteine (NAC) and Inflammatory Bowel Disease (IBD) — General?
We rate the evidence as Grade D (Very Early Research). This rating is based on 1 peer-reviewed studies with 30 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: Inflammatory Bowel Disease (IBD) — General
N-Acetyl Cysteine (NAC) 다른 건강 상태에 대한 근거
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.